Dan Lu, Rajbharan Yadav, Patrick Holder, Eugene Chiang, Shomyseh Sanjabi, Victor Poon, Matthew Bernett, Rajat Varma, Ke Liu, Irene Leung, Liz Bogaert, John Desjarlais, Vittal Shivva, Iraj Hosseini, Saroja Ramanujan
XmAb24306 is a lymphoproliferative interleukin (IL)-15/IL-15 receptor α (IL-15Rα) Fc-fusion protein currently under clinical investigation as an immunotherapeutic agent for cancer treatment. XmAb24306 contains mutations in IL-15 that attenuate its affinity to the heterodimeric IL-15 receptor βγ (IL-15R). We observe substantially prolonged pharmacokinetics (PK) (half-life ∼ 2.5 to 4.5 days) in single- and repeat-dose cynomolgus monkey (cyno) studies compared to wild-type IL-15 (half-life ∼ 1 hour), leading to increased exposure and enhanced and durable expansion of NK cells, CD8+ T cells and CD4-CD8- (double negative [DN]) T cells...
April 19, 2023: European Journal of Pharmaceutical Sciences